Travere Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Travere Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
  • Travere Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $8.02M, a 29.1% decline year-over-year.
  • Travere Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $35.8M, a 20.1% decline year-over-year.
  • Travere Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $44.2M, a 16% increase from 2022.
  • Travere Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $38.1M, a 29% increase from 2021.
  • Travere Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $29.6M, a 25.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $44.2M +$6.1M +16% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 $38.1M +$8.58M +29% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 $29.6M +$5.95M +25.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-20
2020 $23.6M +$2.51M +11.9% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $21.1M +$1.33M +6.73% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $19.8M -$7.1M -26.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $26.9M -$2.23M -7.66% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-24
2016 $29.1M +$3.2M +12.4% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-26
2015 $25.9M +$10M +62.9% Jan 1, 2015 Dec 31, 2015 10-K/A 2018-07-06
2014 $15.9M +$13M +446% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 $2.91M -$19.5M -87% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 $22.4M Jan 1, 2012 Dec 31, 2012 10-K/A 2015-07-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.